Abstract: The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

Abstract: A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel.

Abstract: A combination comprising, spatially separate from one another, a first component and a second component, where the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially, more particularly only partially, an albumin-crosslinking group. Additionally disclosed is a reaction product obtainable by means of the combination, to a medical device, to a medicinal product for innovative therapies, to a kit, to a discharge apparatus, and to a functionalized hyaluronic acid.

Abstract: The invention relates to markers for use in vitro in the prognosis of a clinical outcome (outcome prognosis) of an autologous disc cell transplantation, in the progress assessment/progress monitoring of an autologous disc cell transplantation, in the assessment of the quality of intervertebral disc cells, in the assessment of the quality of an implant and/or advanced therapy medicinal products (ATMP) for the treatment of an intervertebral disc defect, and/or in the diagnosis of an intervertebral disc and/or spinal column defect and a corresponding in vitro method.

Abstract: An in vitro method of prognostically assessing tissue regeneration capacity and/or cellular potency and/or the prospects of success of an implantation and/or transplantation, wherein the transcriptome and/or the gene expression of cells, the gene expression originating from the transcriptome, are analyzed.

Abstract: Disclosed is a multi-chamber applicator comprising an aqueous gelatin solution and an aqueous cross-linking agent solution in separate chambers.

Abstract: To improve a cartilage replacement implant for the biological regeneration of a damaged cartilage area of articular cartilage in the human body, comprising a cell carrier which has a defect-contacting surface for placement on the damaged cartilage area and is formed and designed for colonization with human cells, so that after implantation of the cartilage replacement implant, formation of a gap between adjacent contact surfaces of the implant and surrounding recipient tissue is minimized, it is proposed that the cell carrier rest with surface-to-surface contact on a carrier and be joined to the carrier at a cell carrier surface that faces away from the defect-contacting surface. A method for producing a cartilage replacement implant is also proposed.

Abstract: A therapeutic composition comprising gelatin and a cross-linking agent, for use in biological regenerative methods, which composition can be administered to a target area of the body while ensuring that the suspended cells and/or the growth factors remain in the target area of the body and at the same time eliminating the need for the patient to maintain the treated body area immobilized for unreasonable periods, is disclosed. A method is also disclosed, wherein (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking therapeutic composition which is then administered to the target area; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the target area while forming the cross-linking therapeutic composition.

Abstract: Methods for in-vitro analysis of biological cells and/or microorganisms to determine characteristics such as: degree of differentiation, cell type, donor individuals, culture conditions, purity, lack of natural characteristic, or additional characteristics in comparison to natural characteristics. The methods include the steps of: (a) projecting infrared radiation on a sample; (b) recording spectral characteristics of the sample; (c) deriving a Fourier transform infrared spectrum (FT-IR) from the collected spectral characteristics; (d) generating a derivative transformation of the FT-IR spectrum; (e) comparing said derivative transformation with a derivative of a reference FT-IR spectrum; (f) identifying deviations of said derivative from said reference derivative; and (g) providing an analysis of said characteristics based on the presence of said deviations. In addition, the invention relates to an apparatus for carrying out the disclosed methods.

Abstract: To improve a cartilage replacement implant for the biological regeneration of a damaged cartilage area of articular cartilage in the human body, comprising a cell carrier which has a defect-contacting surface for placement on the damaged cartilage area and is formed and designed for colonization with human cells, so that after implantation of the cartilage replacement implant, formation of a gap between adjacent contact surfaces of the implant and surrounding recipient tissue is minimized, it is proposed that the cell carrier rest with surface-to-surface contact on a carrier and be joined to the carrier at a cell carrier surface that faces away from the defect-contacting surface. A method for producing a cartilage replacement implant is also proposed.

Abstract: A method and apparatus for the in vitro determination and typification of well-differentiated or fully differentiated mammalian cells is disclosed. The method comprises placing a cell sample on a sampling device, irradiating the cells with infrared light, preparing an FT-IR spectrum from the absorption spectrum, calculating derivatives of the FT-IR spectrum and comparing the derivatives to reference FT-IR spectra for known cell types. The apparatus comprises an infrared source and measuring apparatus capable of recording an absorption spectrum, and software for measurement, evaluation, documentation, and derivation of the absorption spectra. Fourier transformation he method is particularly useful for typing cells from tissue biopsies in preparation for cell transplantation.

Abstract: An implant includes a support material, cartilage cells and/or precursor cells thereof, and a cartilage-specific collagen type. A method for preparing the implant, to a therapeutic composition, includes cartilage cells and/or precursor cells thereof and a cartilage-specific collagen type. The implant and the therapeutic composition are suitable in particular for treating damage and/or diseases relating to the human and/or animal musculoskeletal system.

Abstract: A therapeutic composition comprising gelatin and a cross-linking agent, for use in biological regenerative methods, which composition can be administered to a target area of the body while ensuring that the suspended cells and/or the growth factors remain in the target area of the body and at the same time eliminating the need for the patient to maintain the treated body area immobilized for unreasonable periods, is disclosed. A method is also disclosed, wherein (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking therapeutic composition which is then administered to the target area; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the target area while forming the cross-linking therapeutic composition.

Abstract: The invention relates to the use of gelatin and a cross-linking agent to provide a medical glue which forms a cross-linked gelatin gel in an area of application of the human or animal body. According to the invention, (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking medical glue which is then administered to the area of application; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the area of application while forming the cross-linking medical glue.

Abstract: A biocompatible, resorbable composite material having good mechanical properties, and can be populated by cells is provided comprising a first self-supporting layer, which comprises a first material which is insoluble, resorbable and non-gelling under physiological conditions; and a second layer, comprising a cross-linked, gelatinous second material, the second layer having a mainly open-pored structure.